Loading...
XSTO
SEDANA
Market cap125mUSD
Jun 05, Last price  
12.14SEK
1D
-1.62%
1Q
-29.17%
IPO
106.64%
Name

Sedana Medical AB (publ)

Chart & Performance

D1W1MN
P/E
P/S
6.75
EPS
Div Yield, %
Shrs. gr., 5y
3.46%
Rev. gr., 5y
20.06%
Revenues
179m
+16.17%
28,113,00032,155,00040,427,70057,896,20071,645,600141,770,000159,152,000122,865,000153,867,000178,754,000
Net income
-11m
L-82.09%
-1,205,0001,286,000-3,875,700-6,869,100-16,357,700-27,139,000-57,966,000-73,507,000-59,612,000-10,674,000
CFO
-12m
L-69.08%
0238,000495,600-5,778,900-8,700,200-7,846,000-41,221,000-115,433,000-38,061,000-11,769,000
Earnings
Jul 21, 2025

Profile

Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-, which are disposable medical devices that enables the administration of volatile anesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and FlurAbsorb mount to hold the filter during scavenging of anesthetic gas. It also provides AMG-06 Gas Monitor for continuous non-invasive sidestream monitoring of CO2 and anaesthetics concentration in inspired and expired gases; Sedaconda Filling Adapter, a single-use device for safe and easy extraction of isoflurane from a Sedaconda bottle to a Sedaconda Syringe; and various accessories comprising DRYLINE II Water Traps, WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Line. Sedana Medical AB (publ) was founded in 1999 and is headquartered in Danderyd, Sweden.
IPO date
Jun 21, 2017
Employees
84
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
178,754
16.17%
153,867
25.23%
122,865
-22.80%
Cost of revenue
229,501
220,434
226,677
Unusual Expense (Income)
NOPBT
(50,747)
(66,567)
(103,812)
NOPBT Margin
Operating Taxes
726
593
574
Tax Rate
NOPAT
(51,473)
(67,160)
(104,386)
Net income
(10,674)
-82.09%
(59,612)
-18.90%
(73,507)
26.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,396
BB yield
Debt
Debt current
3,334
2,018
5,167
Long-term debt
8,500
5,318
12,319
Deferred revenue
Other long-term liabilities
6,932
Net debt
(182,126)
(374,468)
(590,302)
Cash flow
Cash from operating activities
(11,769)
(38,061)
(115,433)
CAPEX
(2,216)
(515)
(137,783)
Cash from investing activities
(44,673)
(321,957)
(137,783)
Cash from financing activities
(3,571)
(4,857)
(1,507)
FCF
(53,498)
(78,130)
(124,301)
Balance
Cash
193,960
381,804
607,742
Long term investments
46
Excess cash
185,022
374,111
601,645
Stockholders' equity
(264,879)
(254,241)
(194,630)
Invested Capital
1,235,992
1,228,542
1,225,267
ROIC
ROCE
EV
Common stock shares outstanding
99,337
99,337
99,337
Price
Market cap
EV
EBITDA
(29,150)
(59,437)
(79,911)
EV/EBITDA
Interest
215
255
Interest/NOPBT